top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$174.6M

Burn Rate (Qtr)

$21.6M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

AKBA

BPIQ_Logo_RGB-01.jpg

Company Profile

Since our founding in 2007, we’ve put tenacity and innovation to work to develop novel therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization.

Recent Posts

See what the community is saying - click to see full post.

Exciting conferences in Kidney, Liver, and Alzheimer's disease! - 2022 Investor Hub

March 2022 Big-Mover™ Stocks and Movers to Watch Report

Biotech PDUFAs to Watch March 2022 - RYTM, TXMD, LPCN

J.P. Morgan Healthcare Conference

Smid-Cap Biopharmas Presenting Clinical Updates at Upcoming 2021 Conferences (Multiple Sclerosis, Kidney Disease, Alzheimer's Disease)

Q3 Corporate Quarterly Updates: Small and Mid-Cap Biotech Companies to Watch

bottom of page